Maraviroc Patent Expiration

Maraviroc is Used for treating patients infected with CCR5-tropic HIV-1. It was first introduced by Viiv Healthcare Co in its drug Selzentry on Aug 6, 2007. 3 different companies have introduced drugs containing Maraviroc.


Maraviroc Patents

Given below is the list of patents protecting Maraviroc, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Selzentry US6586430 CCR5 modulators Dec 01, 2019

(Expired)

Viiv Hlthcare
Selzentry US6586430 CCR5 modulators Dec 01, 2019

(Expired)

Viiv Hlthcare
Selzentry US6667314 Tropane derivatives useful in therapy Aug 06, 2021

(Expired)

Viiv Hlthcare
Selzentry US6667314 Tropane derivatives useful in therapy Aug 06, 2021

(Expired)

Viiv Hlthcare
Selzentry US6667314

(Pediatric)

Tropane derivatives useful in therapy Feb 06, 2022

(Expired)

Viiv Hlthcare
Selzentry US7368460 Tropane derivatives useful in therapy Nov 25, 2022

(Expired)

Viiv Hlthcare
Selzentry US7368460

(Pediatric)

Tropane derivatives useful in therapy May 25, 2023

(Expired)

Viiv Hlthcare
Selzentry US7576097 Tropane derivatives useful in therapy May 25, 2021

(Expired)

Viiv Hlthcare
Selzentry US7576097 Tropane derivatives useful in therapy May 25, 2021

(Expired)

Viiv Hlthcare
Selzentry US7576097

(Pediatric)

Tropane derivatives useful in therapy Nov 25, 2021

(Expired)

Viiv Hlthcare


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Maraviroc Generics

Several generic applications have been filed for Maraviroc. The first generic version for Maraviroc was by Hetero Labs Ltd Unit Iii and was approved on Feb 7, 2022. And the latest generic version is by I 3 Pharmaceuticals Llc and was approved on Aug 17, 2023.

Given below is the list of companies who have filed for Maraviroc generic.


1. HETERO LABS LTD III

Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Maraviroc. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.

Strength Dosage Form Availability Application Pathway TE code Launch Date
150MG tablet Prescription ORAL AB Feb 7, 2022
300MG tablet Prescription ORAL AB Feb 7, 2022


2. I 3 PHARMS

I 3 Pharmaceuticals Llc has filed for 2 different strengths of generic version for Maraviroc. Given below are the details of the strengths of this generic introduced by I 3 Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
150MG tablet Prescription ORAL AB Aug 17, 2023
300MG tablet Prescription ORAL AB Aug 17, 2023